Last reviewed · How we verify
Stem Cell Regenerative Therapy
At a glance
| Generic name | Stem Cell Regenerative Therapy |
|---|---|
| Sponsor | Truway Health, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Exosomes Effect on Visual Function in CVI
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). (PHASE3)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy (PHASE1, PHASE2)
- Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss (EARLY_PHASE1)
- Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis (PHASE1, PHASE2)
- Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stem Cell Regenerative Therapy CI brief — competitive landscape report
- Stem Cell Regenerative Therapy updates RSS · CI watch RSS
- Truway Health, Inc. portfolio CI